Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

Throughout ‘the year of the election’ – as 2024 was widely known – we were working with politicians and decision-makers to ...

Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...

The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical ...